I-Evista (i-Raloxifene HCI) ihlehlisa ingozi yomdlavuza webele wesibindi

Yini i-Evista ?:

I-Evista (i-raloxifene hydrochloride) isisetshenziswa se-estrogen receptor modulator (SERM). Isetshenziselwa ukwelapha i-osteoporosis futhi akuyona i-hormone.

U-Evista Uphatha Amathoni Asemthonjeni Kanye Nengozi Ephansi Ye-Cancer Yomlomo:

I-Evista isetshenziselwa ukuvimbela nokwelashwa kwe-osteoporosis (bone bone thinning) kwabesifazane be-postmenopausal. Ngo-2007, kwavunyelwa ukunciphisa ingozi yomdlavuza webele we-invasive kumama we-postmenopausal abane-osteoporosis kanye nabesifazane be-postmenopausal abasengozini enkulu yomdlavuza webele we-invasive.

U-Evista akuyona imithi yokwelapha umdlavuza webele, kodwa ingasetshenziswa ukusiza amacala omdlavuza wesifuba we-estrogen-receptor engavamile. Akunciphisi ingozi yokuphindaphinda umdlavuza webele we-invasive. Abesifazane abanomdlavuza webele webele ngenxa yokuguquka kwezakhi zofuzo ( BRCA1 , BRCA2 ) ngeke bazuze ngokuthatha u-Evista.

Indlela Evista Esebenza ngayo:

I-Evista ibopha izimpendulo ze-estrogen kumaseli, kudala ukuvimbela futhi kubangele ukujikeleza i-estrogen ukuthatha ezinye izindlela emzimbeni wakho. Linciphisa isifo se-postmenopausal esincane futhi sandisa isibindi samaminerali (BMD). Lokhu kubangela amathambo anamandla futhi ingozi encane yokuhlukana. Inzuzo eyengeziwe ka-Evista yukuthi ukunciphisa amazinga okulingana kanye ne- LDL ye-cholesterol . Ezingxenyeni zamabele nezibeletho, zisebenza njengomphikisi we-estrogen.

Amathoni aphuzi Ngesikhathi Nengemva Kokuphela kwesikhathi:

Ngesikhathi nangemva kokuya esikhathini, umzimba wakho ukhiqiza i-estrogen engaphansi, okwenza ukuba umzimba ube mncane.

Abesifazane abaningi bathatha izidakamizwa ze-osteoporosis ukuvikela nokuqinisa amathambo abo ngemva kokuya esikhathini. I-Fosamax, i-Boniva, ne-Evista inqunyelwe abesifazane besimo se-postmenopausal, kanye ne-Vitamin D kanye ne-calcium supplements kanye nokuvivinya umzimba, ukugcina impilo ye-bone nokuvimbela ama-fractures kanye nama-breaks. Uma amathambo akho elula, usengozini yokuqhekeka emgodini wakho, izigqoko nezinsikazi.

Evista Uma kuqhathaniswa neTamoxifen:

U-Evista waqhathaniswa noTamoxifen ocwaningweni lwe- STAR engu-5, futhi akutholakalanga ukuthi usebenza ngokuphumelelayo ekunciphiseni izifo zomdlavuza webele we-invasive. Kodwa-ke, ukwelashwa kwe-Evista kwabangela amacala ambalwa we-vein thrombosis ejulile, i-embolism ye-pulmonary, i-cataracts nomdlavuza we-endometrial (imiphumela engavamile) kuneTamoxifen.

Izincomo ngenkathi kuthatha u-Evista:

Abesifazane abazohamba isikhathi eside (ukuphumula ekuhlinzeni, ukuphumula ukulala, ukuhamba nokuhamba okukhawulelwe) kufanele bayeke ukuthatha u-Evista okungenani amahora angu-72 ngaphambili, futhi phakathi nesikhathi, isikhathi sokuhlala. Lokhu kungenxa yokuthi u-Evista angandisa ingozi yegazi. Uma uthatha u-Evista, qiniseka ukuthi uthatha izithako ze-calcium ne-vitamin D, futhi uhlanganyele ekuzivocavoca umzimba okuvamile, ukuze uthole inzuzo enkulu empilweni yakho yethambo. Yeka noma unqande ukubhema , i-caffeine, nophuzo oludakayo ngenkathi u-Evista, njengoba lezo zinto zenza ukuba amathambo ahlasele.

Ubani Ongayithathi I-Evista:

Ungathathi u-Evista uma:

Kutholakala njengo:

I-Evista itholakala ngamaphilisi angu-60 mg, ngokwemithi kuphela. Kuthathwa kanye ngosuku, noma ngaphandle kokudla.

Okuqhamuka uma udla imishanguzo:

I-Evista ingabangela le mibi ejwayelekile:


Akuwona wonke umuntu okufanele athathe u-Evista, ngoba angandisa ingozi yamacilongo egazi emilenzeni (i-vein thrombosis ejulile), inhliziyo (i-pulmonary embolism), namehlo (i-retinal vein thrombosis).

Bheka udokotela wakho uma unezi zimpawu ngenkathi uthatha u-Evista:

I-Evista ayibangeli ubuhlungu besisu noma isisa, futhi ayibangeli ukuphuma kwegazi.

Imithombo:
Evista.com. I-Osteoporosis ne-Cancer Invastable Breast Cancer. © 2008.

I-FDA. Isikhungo Sokuhlolwa Kwezidakamizwa Nokucwaninga. I-FDA ivumela ukusetshenziswa okusha kwe-Evista (raloxifene hydrochloride). Idethi idalwe: Septemba 17, 2007.

I-FDA News. I-Raloxifene hydrochloride. Ngo-September 17, 2007.